FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301393330> ?p ?o ?g. }

• W4301393330 endingPage "1049" @default.
• W4301393330 startingPage "1039" @default.
• W4301393330 abstract "Abstract Objective Amyloid positron emission tomography (PET) can reliably detect senile plaques and fluorinated ligands are approved for clinical use. However, the clinical impact of amyloid PET imaging is still under investigation. The aim of this study was to evaluate the diagnostic impact and clinical utility in patient management of amyloid PET using 18 F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease (AD). We also aimed to determine the cutoffs for amyloid positivity for quantitative measures by investigating the agreement between quantitative and visual assessments. Methods Ninety-nine patients suspected of having AD underwent 18 F-florbetapir PET at five institutions. Site-specialized physicians provided a diagnosis of AD or non-AD with a percentage estimate of their confidence and their plan for patient management in terms of medication, prescription dosage, additional diagnostic tests, and care planning both before and after receiving the amyloid imaging results. A PET image for each patient was visually assessed and dichotomously rated as either amyloid-positive or amyloid-negative by four board-certified nuclear medicine physicians. The PET images were also quantitatively analyzed using the standardized uptake value ratio (SUVR) and Centiloid (CL) scale. Results Visual interpretation obtained 48 positive and 51 negative PET scans. The amyloid PET results changed the AD and non-AD diagnosis in 39 of 99 patients (39.3%). The change rates of 26 of the 54 patients (48.1%) with a pre-scan AD diagnosis were significantly higher than those of 13 of the 45 patients with a pre-scan non-AD diagnosis ( χ 2 = 5.334, p = 0.0209). Amyloid PET results also resulted in at least one change to the patient management plan in 42 patients (42%), mainly medication (20 patients, 20%) and care planning (25 patients, 25%). Receiver-operating characteristic analysis determined the best agreement of the quantitative assessments and visual interpretation of PET scans to have an area under the curve of 0.993 at an SUVR of 1.19 and CL of 25.9. Conclusion Amyloid PET using 18 F-florbetapir PET had a substantial clinical impact on AD and non-AD diagnosis and on patient management by enhancing diagnostic confidence. In addition, the quantitative measures may improve the visual interpretation of amyloid positivity." @default.
• W4301393330 created "2022-10-05" @default.
• W4301393330 creator A5005498918 @default.
• W4301393330 creator A5008400314 @default.
• W4301393330 creator A5010300845 @default.
• W4301393330 creator A5011325858 @default.
• W4301393330 creator A5012313929 @default.
• W4301393330 creator A5013055601 @default.
• W4301393330 creator A5013379011 @default.
• W4301393330 creator A5015193671 @default.
• W4301393330 creator A5015519992 @default.
• W4301393330 creator A5030033498 @default.
• W4301393330 creator A5030217409 @default.
• W4301393330 creator A5034642477 @default.
• W4301393330 creator A5038000762 @default.
• W4301393330 creator A5052262712 @default.
• W4301393330 creator A5053859196 @default.
• W4301393330 creator A5056125044 @default.
• W4301393330 creator A5066539878 @default.
• W4301393330 creator A5067446953 @default.
• W4301393330 creator A5078474692 @default.
• W4301393330 creator A5078924905 @default.
• W4301393330 creator A5079975902 @default.
• W4301393330 creator A5085486382 @default.
• W4301393330 date "2022-10-04" @default.
• W4301393330 modified "2023-10-03" @default.
• W4301393330 title "Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study" @default.
• W4301393330 cites W1747781838 @default.
• W4301393330 cites W1847168837 @default.
• W4301393330 cites W1979461960 @default.
• W4301393330 cites W1993023011 @default.
• W4301393330 cites W2008854521 @default.
• W4301393330 cites W2040174321 @default.
• W4301393330 cites W2058161128 @default.
• W4301393330 cites W2076235442 @default.
• W4301393330 cites W2082429191 @default.
• W4301393330 cites W2115017507 @default.
• W4301393330 cites W2124030567 @default.
• W4301393330 cites W2148080316 @default.
• W4301393330 cites W2151384687 @default.
• W4301393330 cites W2152575748 @default.
• W4301393330 cites W2152663843 @default.
• W4301393330 cites W2166536611 @default.
• W4301393330 cites W2167311298 @default.
• W4301393330 cites W2169388901 @default.
• W4301393330 cites W2256147203 @default.
• W4301393330 cites W2320443948 @default.
• W4301393330 cites W2342522068 @default.
• W4301393330 cites W2510151956 @default.
• W4301393330 cites W2529547155 @default.
• W4301393330 cites W2545072337 @default.
• W4301393330 cites W2560999412 @default.
• W4301393330 cites W2568095284 @default.
• W4301393330 cites W2742954524 @default.
• W4301393330 cites W2747391742 @default.
• W4301393330 cites W2762850865 @default.
• W4301393330 cites W2767029446 @default.
• W4301393330 cites W2769863834 @default.
• W4301393330 cites W2849227165 @default.
• W4301393330 cites W2897964327 @default.
• W4301393330 cites W2930696305 @default.
• W4301393330 cites W3010723816 @default.
• W4301393330 cites W3160870314 @default.
• W4301393330 cites W4210880745 @default.
• W4301393330 cites W4247665917 @default.
• W4301393330 doi "https://doi.org/10.1007/s12149-022-01792-y" @default.
• W4301393330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36194355" @default.
• W4301393330 hasPublicationYear "2022" @default.
• W4301393330 type Work @default.
• W4301393330 citedByCount "4" @default.
• W4301393330 countsByYear W43013933302023 @default.
• W4301393330 crossrefType "journal-article" @default.
• W4301393330 hasAuthorship W4301393330A5005498918 @default.
• W4301393330 hasAuthorship W4301393330A5008400314 @default.
• W4301393330 hasAuthorship W4301393330A5010300845 @default.
• W4301393330 hasAuthorship W4301393330A5011325858 @default.
• W4301393330 hasAuthorship W4301393330A5012313929 @default.
• W4301393330 hasAuthorship W4301393330A5013055601 @default.
• W4301393330 hasAuthorship W4301393330A5013379011 @default.
• W4301393330 hasAuthorship W4301393330A5015193671 @default.
• W4301393330 hasAuthorship W4301393330A5015519992 @default.
• W4301393330 hasAuthorship W4301393330A5030033498 @default.
• W4301393330 hasAuthorship W4301393330A5030217409 @default.
• W4301393330 hasAuthorship W4301393330A5034642477 @default.
• W4301393330 hasAuthorship W4301393330A5038000762 @default.
• W4301393330 hasAuthorship W4301393330A5052262712 @default.
• W4301393330 hasAuthorship W4301393330A5053859196 @default.
• W4301393330 hasAuthorship W4301393330A5056125044 @default.
• W4301393330 hasAuthorship W4301393330A5066539878 @default.
• W4301393330 hasAuthorship W4301393330A5067446953 @default.
• W4301393330 hasAuthorship W4301393330A5078474692 @default.
• W4301393330 hasAuthorship W4301393330A5078924905 @default.
• W4301393330 hasAuthorship W4301393330A5079975902 @default.
• W4301393330 hasAuthorship W4301393330A5085486382 @default.
• W4301393330 hasBestOaLocation W43013933301 @default.
• W4301393330 hasConcept C126322002 @default.
• W4301393330 hasConcept C126838900 @default.
• W4301393330 hasConcept C142724271 @default.

• next